Navigation Links
Bayer's Investigational Compound Radium-223 Chloride Met its Primary Endpoint of Significantly Improving Overall Survival in a Phase III Trial in Patients with Castration-Resistant Prostate Cancer That Has Spread to the Bone
Date:6/5/2011

WAYNE, N.J., June 6, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. today announced that the Phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) trial evaluating Bayer's investigational compound, radium-223 chloride, which is exclusively licensed from Algeta ASA, in patients with castration-resistant prostate cancer (CRPC) and bone metastases met its primary endpoint by significantly improving overall survival.  Based on a recommendation from the Independent Data Monitoring Committee (IDMC), following a pre-planned interim analysis, the study will be stopped and patients on the placebo arm will be offered treatment with radium-223 chloride.  The overall survival result was statistically significant (two-sided p-value = 0.0022, HR = 0.699, the median overall survival was 14.0 months for radium-223 chloride and 11.2 months for placebo).  The complete results from the study will be presented at an upcoming scientific meeting.

The safety and tolerability of radium-223 chloride were consistent with previous Phase I and Phase II trial outcomes and did not show any new or unexpected changes in the safety profile of radium-223 chloride.  Common adverse events from the ALSYMPCA trial included diarrhea, neutropenia and thrombocytopenia.

Radium-223 chloride is an investigational agent and is not approved by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) or other health authorities.

"We are pleased that radium-223 chloride met its primary endpoint of significantly improving overall survival in patients with CRPC and bone metastases, and are hopeful about the potential of radium-223 chloride for this patient population," said Kemal Malik, MD, Head of Global Development and member of the Bayer HealthCare Executive Committee.  

The company is evaluating the filing strategy for radium-223 chloride based on the IDMC's recommendation to stop thi
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Boehringer Ingelheim to present new data at ASCO annual meeting regarding its investigational compound afatinib in EGFR-mutation positive patients with advanced NSCLC
2. Bayer to Present Data on Investigational Oncology Compounds at 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO)
3. FDA Grants Orphan Drug Designation for Nektars Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer
4. Amylin to Present Data Showing Investigational Metreleptin Treatment Led to Long-Term Improvements in Diabetes and Lipid Control in Patients with Lipodystrophy
5. Investigational Drug May Reduce Involuntary Movements in People With Parkinsons Disease
6. Update on Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710
7. Positive Phase 2 Results Reported with Boehringer Ingelheims Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients
8. FDA Accepts Investigational New Drug Application for ARI-3030MO; First in Man Clinical Trial to Begin During First Quarter of 2011
9. Takeda Submits New Drug Application in the U.S. for Azilsartan Medoxomil Plus Chlorthalidone, an Investigational Fixed-Dose Combination for the Treatment of Hypertension
10. Lilly Marks Major Milestone for Mirror Portfolio with Agreement by Independent Fund to License First Two Investigational Medicines
11. FDA Grants Orphan Drug Designation to Bayers Investigational Compound Regorafenib for the Treatment of Gastrointestinal Stromal Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... VIEW, Calif. , July 30, 2015 ... it will release its second quarter 2015 financial results ... 2015.   In conjunction with the release, the Company ... at 5:00 p.m. Eastern Time on ... of the quarter and other business developments. ...
(Date:7/30/2015)... , July 30, 2015  Unichem Pharmaceuticals ( ... lot of Hydrochlorothiazide tablets 25 mg 1000-count bottle to ... a precautionary measure due to the identification of a ... The risk associated with mistakenly taking ... the increased probability of experiencing Clopidogrel,s side effects which ...
(Date:7/30/2015)... -- Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ) ... patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics ... notice it received on May 21, 2015 from the ... was below certain of the Exchange,s continued listing standards, ... the NYSE MKT Company Guide, due to the delay ...
Breaking Medicine Technology:IRIDEX Announces Second Quarter 2015 Conference Call and Release Date 2Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2
... KNSY ), today announced that it has entered into ... under which DSM has agreed to acquire all of the common ... a merger with a subsidiary of DSM, for $38.50 per share ... entered into the merger agreement with DSM, as the transaction will ...
... Synteract , Inc., a full-service contract research organization ... therapies to combat the growing issue of antibiotic resistance, ... fundraising walk to benefit the Cystic Fibrosis (CF) ... behalf of Aptalis Pharma) are also working together on ...
Cached Medicine Technology:Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash 2Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash 3Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash 4Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash 5Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash 6Synteract and Rempex Partner in "Great Strides" Walk to Support Cystic Fibrosis Cure 2
(Date:7/31/2015)... ... July 31, 2015 , ... Facebook, Twitter, Linkedin and ... their social media profiles to better connect with the public. The agency website ... information, share insights and opinions. The Rally Insurance Group, Inc.’s pledge to provide ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... According to ... cosmetic experts gathered to see if they could reach a consensus on the steps ... augmentation and facelifts. Overall, the group reached 90 percent consensus on a series of ...
(Date:7/31/2015)... ... July 31, 2015 , ... The 2015 New York ... family members, medical professionals, and researchers, covering a variety of topics related to ... collaborative effort between the Mesothelioma Applied Research Foundation and Memorial Sloan Kettering Cancer ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... been recognized in the 2015 Aster Awards national competition for a marketing communications ... Ocean City and surrounding communities in Coastal Maryland and Southern Delaware. , A ...
(Date:7/31/2015)... ... 31, 2015 , ... Recently, ZKB filed another federal lawsuit ... (Case No. 3:15-cv-00397) involving the Implanon® contraceptive implant . , As described ... Implanon® implants, inability to locate the implants, unsuccessful and invasive attempts at implant ...
Breaking Medicine News(10 mins):Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3Health News:New York Area Mesothelioma Specialists to Present at Conference 2Health News:New York Area Mesothelioma Specialists to Present at Conference 3Health News:Mullin/Ashley Associates Wins in the 2015 Aster Awards National Competition for Excellence in Medical Marketing 2Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 2Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 3
... MAQUET Cardiovascular LLC,announced today that it was served ... (Terumo CSC) in the United States District,Court for ... that,MAQUET,s VASOVIEW Endoscopic Vessel Harvesting Systems infringe a ... patent infringement complaints against,Terumo CSC and Terumo Corporation ...
... SANTA YNEZ VALLEY, Calif., Sept. 2 Platinum Performance,client McLain ... Summer Olympics in Beijing, China, on August 19, as "probably ... sport.", Winning the first ever jump-off in Olympic Games ... the Team Show Jumping title at the Hong Kong,Olympic Equestrian ...
... CORAL GABLES, Fla., Sept. 2 MBF ... publicly traded special purpose,acquisition company, announced today ... MBH,s proposed acquisition of Critical Homecare Solutions,Holdings, ... stock purchase,agreement dated February 6, 2008 (the ...
... LANCASTER, Pa., Sept. 2 Herley Industries,Inc. (Nasdaq: ... manufacture of,microwave technology solutions for the defense, aerospace and ... a division of Jefferies & Company, Inc., as its ... strategic alternatives., Myron Levy, Chairman and CEO, said, ...
... and Providers Contain Costs and ... Improve Patient Outcomes Together, HOUSTON, Sept. ... Oncology, a service division that offers a first-time,opportunity for oncologists ... for the complexity of cancer,care. With a unique focus on ...
... even a year after routine was stopped, study says ... may help treat memory problems in adults, according to ... 138 people age 50 and older at increased risk ... led to modest improvements in cognitive function in adults ...
Cached Medicine News:Health News:MAQUET Cardiovascular Responds to Terumo Complaint About VASOVIEW Endoscopic Vessel Harvesting Systems 2Health News:Platinum Performance Clients Take Home Medals for the USA 2Health News:MBF Healthcare Acquisition Corp. Amends Stock Purchase Agreement With Critical Homecare Solutions Holdings, Inc. to Extend Termination Date to October 31, 2008 2Health News:MBF Healthcare Acquisition Corp. Amends Stock Purchase Agreement With Critical Homecare Solutions Holdings, Inc. to Extend Termination Date to October 31, 2008 3Health News:MBF Healthcare Acquisition Corp. Amends Stock Purchase Agreement With Critical Homecare Solutions Holdings, Inc. to Extend Termination Date to October 31, 2008 4Health News:Herley Industries, Inc. Engages Jefferies Quarterdeck to Explore Strategic Alternatives 2Health News:US Oncology Launches New Services Division: Innovent Oncology 2Health News:US Oncology Launches New Services Division: Innovent Oncology 3Health News:US Oncology Launches New Services Division: Innovent Oncology 4Health News:Exercise May Help Prevent Age-Related Memory Loss 2
Straight shafts with 16 mm long platform. Lengthwise serrated jaws with cross serrated tips. Serrated handle with polished finish. Platform: 2.4 mm wide....
Straight shafts with fitted v-grooved 15 mm platform. Serrated handle with polished finish....
Smooth tip forceps allow the surgeon to manipulate and smooth the corneal flap in Lasik procedures. Tip angled 10 mm from tip. Manufactured in titanium....
Straight shafts with 1 x 2 teeth. Flat handle with haoles and polished finish. Delicate teeth. Most popular size or model....
Medicine Products: